Drugs / Imiquimod
Imiquimod
also known as
Aldara · IMQ · Zyclara · Aldara (Imiquimod) · Aldara (imiquimod) 5% cream - 250 mg / packet · Aldara (imiquimod) cream 5% · Aldara 5% Topical Cream · Aldara cream · +7 more
Other / unclassified targets TLR7 via activation
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | ZYCLARA | — | 2011-03-24 – 2011-07-15 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | ALDARA | — | 2004-03-02 – 2007-03-22 | fda.gov ↗ |
| Approved | EU (EMA) | Aldara | — | 1998-09-18 | europa.eu ↗ |
| Approved | US (FDA) | ALDARA | — | 1997-02-27 | fda.gov ↗ |
Trials 124 · started per year
today
US approved 1997
EU approved 1998
1
2
2
4
1
3
11
5
5
14
5
6
3
5
7
5
4
8
4
4
6
2
3
2
2
3
3
2
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials · 1 met primary | ||||||
| Phase 0 | NCT05838599 | Jul 2023 → Jun 2027 expected | mycosis fungoides | Northwestern University | Recruiting | No outcome recorded |
| Phase 0 | NCT05468606 | Feb 2023 → Dec 2024 | Plasmodium falciparum malaria | Leiden University Medical Center | Unknown | Met primary |
| Phase 0 | NCT04883645 | Apr 2022 → Jun 2023 | oral cavity squamous cell carcinoma | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 0 | NCT03196180 | Oct 2019 → Nov 2020 | cervical intraepithelial neoplasia grade 2/3, uterine cervix carcinoma in situ | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 0 | NCT03116659 | Feb 2018 → Dec 2020 | primary cutaneous T-cell lymphoma | James J. Peters Veterans Affairs Medical Center | Unknown | No outcome recorded |
| Phase 0 | NCT03276832 | Dec 2017 → Oct 2019 | cutaneous melanoma, metastatic melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT01678352 | Oct 2012 → Nov 2017 | grade II glioma | Frank Lieberman | Completed | No outcome recorded |
| Phase 117 trials | ||||||
| Phase 1 | NCT03982004 | Sep 2020 → Mar 2021 | breast cancer | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04219358 | Mar 2019 → Jun 2020 | actinic cheilitis | Hospital de Clinicas de Porto Alegre | Terminated | No outcome recorded |
| Phase 1 | NCT03472976 | Jun 2018 → Mar 2019 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03071679 | Feb → Mar 2017 | — | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02889159 | Jun 2016 → Feb 2023 | skin disorder | University of Michigan | Completed | No outcome recorded |
| Phase 1 | NCT02234921 | Oct 2014 → Aug 2018 | prostate adenocarcinoma | UbiVac | Completed | No outcome recorded |
| Phase 1 | NCT02052687 | Jan → Jun 2014 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01400672 | Jul 2012 → Mar 2016 | diffuse intrinsic pontine glioma | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 1 | NCT01792505 | Oct 2009 → Nov 2014 | malignant glioma | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00988559 | Sep 2009 → Jul 2016 | cervical intraepithelial neoplasia grade 2/3, virus associated tumor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT00865644 | Mar 2009 → Apr 2010 | neurofibroma, neurofibromatosis type 1 | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00788164 | Nov 2008 → Aug 2023 | cervical cancer, dysplasia of cervix, human papilloma virus infection | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT00453050 | Mar 2006 → Mar 2009 | cutaneous melanoma, metastatic malignant neoplasm | University of Oklahoma | Completed | No outcome recorded |
| Phase 1 | NCT00142454 | Aug 2005 → Apr 2006 | melanoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00118313 | Nov 2004 → Jul 2006 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1 | NCT00079300 | Jan 2004 → Aug 2005 | skin carcinoma | National Naval Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01567683 | — | — | Moberg Pharma AB | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07679841 | Sep 2026 → Sep 2029 expected | vulvar squamous cell carcinoma | Centre Leon Berard | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07251413 | Oct 2025 → Dec 2028 expected | skin basal cell carcinoma | Instituto Oncológico Dr Rosell | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07210775 | Oct 2025 → Oct 2027 expected | oral mucosa leukoplakia | University of Southern California | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01421017 | Aug 2011 → Jul 2016 | breast carcinoma | NYU Langone Health | Completed | No outcome recorded |
| Phase 1/2 | NCT01191034 | Aug 2010 → Aug 2012 | metastatic melanoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
| Phase 1/2 | NCT00785122 | Jun 2008 → Jan 2011 | colorectal carcinoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT02452307 | Apr 2004 → Oct 2017 | prostate carcinoma | University Hospital Tuebingen | Unknown | No outcome recorded |
| Phase 224 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT06686043 | Aug 2024 → Aug 2026 overdue | cervical carcinoma, human papillomavirus-related squamous cell carcinoma, vaginal carcinoma, vulvar carcinoma | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT05028322 | Nov 2021 → Dec 2024 | cirrhosis of liver, hepatitis B virus infection | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| Phase 2 | NCT03534947 | Jul 2019 → Mar 2025 | invasive carcinoma, skin basal cell carcinoma | Melanoma Institute Australia | Completed | No outcome recorded |
| Phase 2 | NCT03760250 | Feb → Sep 2019 | keloid | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 2 | NCT03233412 | Jan 2018 → Jan 2020 | cervical cancer, intraepithelial neoplasia | Barretos Cancer Hospital | Completed | Met primary |
| Phase 2 | NCT03180684 | Aug 2017 → Jul 2020 | human papilloma virus infection, precancerous condition, vulvar intraepithelial neoplasia | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02960815 | Nov 2016 → Jun 2017 | — | University of Lausanne Hospitals | Completed | No outcome recorded |
| Phase 2 | NCT02864147 | Jul 2016 → May 2022 | cervical intraepithelial neoplasia | Yale University | Completed | Missed primary |
| Phase 2 | NCT01909752 | Jul 2013 → Nov 2016 | non-small cell lung carcinoma | UbiVac | Completed | No outcome recorded |
| Phase 2 | NCT01731652 | Feb 2013 → Feb 2014 | in situ carcinoma, non-invasive bladder urothelial carcinoma | Telormedix SA | Completed | No outcome recorded |
| Phase 2 | NCT03914417 | Jan 2013 → Apr 2015 | actinic keratosis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT00899574 | May 2009 → Apr 2011 | breast cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT00941811 | Dec 2008 → Dec 2009 | anogenital human papillomavirus infection | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT00821964 | Dec 2008 → Nov 2012 | male breast carcinoma, skin cancer | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00979550 | Oct 2008 → Aug 2013 | capillary malformation | Henry Vasconez | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00799110 | Aug 2008 → Dec 2024 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Beth Israel Deaconess Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00651703 | Apr 2008 → Dec 2009 | melanoma | Cytos Biotechnology AG | Completed | No outcome recorded |
| Phase 2 | NCT01380314 | Mar 2008 → Mar 2010 | cutaneous leishmaniasis | Foundation Fader | Completed | No outcome recorded |
| Phase 2 | NCT00596336 | Oct 2007 → Dec 2011 | chronic lymphocytic leukemia/small lymphocytic lymphoma | The Royal Bournemouth Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00273910 | Jan 2006 → May 2010 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00601016 | Mar 2005 → Sep 2006 | capillary hemangioma | St. Justine's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00189267 | Nov 2002 → Sep 2005 | actinic keratosis | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 2 | NCT00031759 | Jun 1999 → Jul 2004 | cervical cancer, precancerous condition | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 2 | NCT01611480 | ? → Jan 2013 | actinic keratosis | Moberg Pharma AB | Completed | No outcome recorded |
| Phase 2/36 trials · 2 met primary | ||||||
| Phase 2/3 | NCT04083157 | Aug 2019 → Dec 2020 | hepatitis B virus infection, inflammatory bowel disease | The University of Hong Kong | Completed | Met primary |
| Phase 2/3 | NCT03307902 | Oct 2016 → Mar 2019 | hepatitis B virus infection | The University of Hong Kong | Completed | No outcome recorded |
| Phase 2/3 | NCT02621112 | Jan 2016 → Dec 2018 | kidney failure | The University of Hong Kong | Completed | Met primary |
| Phase 2/3 | NCT02130323 | Feb 2015 → Dec 2016 | cervical intraepithelial neoplasia | United States Naval Medical Center, San Diego | Completed | No outcome recorded |
| Phase 2/3 | NCT01088737 | Jan 2011 → Dec 2021 | lentigo | Medical University of Graz | Unknown | No outcome recorded |
| Phase 2/3 | NCT00384124 | Nov 2006 → Nov 2008 | Bowen disease of the skin | Brooke Army Medical Center | Unknown | No outcome recorded |
| Phase 327 trials · 3 met primary · 4 missed | ||||||
| Phase 3 | NCT05212246 | Oct 2026 → Oct 2032 expected | skin basal cell carcinoma | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03289260 | Nov 2021 → Nov 2024 | anogenital human papillomavirus infection | Medical University Innsbruck | Unknown | No outcome recorded |
| Phase 3 | NCT02669459 | May 2016 → Mar 2019 | cervical intraepithelial neoplasia | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02242929 | Jan 2016 → Dec 2017 | nodular basal cell carcinoma | Maastricht University Medical Center | Unknown | Missed primary |
| Phase 3 | NCT02059499 | Dec 2015 → Dec 2023 | HIV infectious disease, squamous cell intraepithelial neoplasia | AIDS Malignancy Consortium | Completed | Mixed |
| Phase 3 | NCT02394132 | Aug 2015 → Dec 2021 | lentigo maligna melanoma | Melanoma and Skin Cancer Trials Limited | Completed | No outcome recorded |
| Phase 3 | NCT02385188 | May 2015 → Mar 2018 | vulval Paget disease | University Medical Center Nijmegen | Completed | No outcome recorded |
| Phase 3 | NCT02329171 | Dec 2014 → Jun 2016 | cervical intraepithelial neoplasia | Maastricht University Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT02135419 | Sep 2014 → Aug 2021 | HIV infectious disease, anal carcinoma, human papilloma virus infection, squamous cell intraepithelial neoplasia | AIDS Malignancy Consortium | Completed | Met primary |
| Phase 3 | NCT02103023 | Mar → Nov 2014 | influenza | The University of Hong Kong | Completed | Met primary |
| Phase 3 | NCT02120898 | Oct 2013 → Apr 2014 | actinic keratosis | Actavis Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01861535 | Jun 2013 → Feb 2021 | vulvar intraepithelial neoplasia | Medical University of Graz | Completed | Met primary |
| Phase 3 | NCT01283763 | May 2013 → Sep 2017 | cervical intraepithelial neoplasia | Medical University of Vienna | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT01720407 | Dec 2012 → Oct 2019 | lentigo maligna melanoma | Nantes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01686152 | Sep 2012 → Aug 2013 | actinic keratosis | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 3 | NCT00735462 | Aug 2008 → Jul 2009 | anogenital human papillomavirus infection | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00674739 | May 2008 → Jul 2009 | anogenital human papillomavirus infection | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00859105 | Feb → Nov 2008 | actinic keratosis | Apotex Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00294320 | Feb 2006 → Jan 2007 | actinic keratosis | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 3 | NCT00257530 | Dec 2005 → Jun 2006 | cutaneous leishmaniasis | Drugs for Neglected Diseases | Completed | Missed primary |
| Phase 3 | NCT00230373 | Nov 2005 → Jun 2007 | localized scleroderma | University of Alberta | Withdrawn | No outcome recorded |
| Phase 3 | NCT00147771 | Sep 2005 → Sep 2009 | localized scleroderma | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT00175643 | Feb → Nov 2005 | actinic keratosis | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT00189280 | May 2003 → Oct 2007 | basal cell carcinoma | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 3 | NCT00066872 | Oct 2002 → Apr 2010 | skin carcinoma | Queen's Medical Center | Completed | Missed primary |
| Phase 3 | NCT00189306 | Mar 2001 → Apr 2007 | superficial multifocal basal cell carcinoma | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00189241 | Feb 2001 → Feb 2007 | basal cell carcinoma | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 422 trials · 1 met primary | ||||||
| Phase 4 | NCT06840470 | Mar 2025 → Dec 2026 expected | sebaceous gland disorder | University of Michigan | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06356012 | Apr 2024 → Dec 2026 expected | cervical intraepithelial neoplasia grade 2/3 | Barretos Cancer Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04842422 | Apr → Aug 2021 | actinic keratosis | Medical University of Graz | Completed | No outcome recorded |
| Phase 4 | NCT01453179 | Oct 2011 → Mar 2015 | actinic keratosis | MEDA Pharma GmbH & Co. KG | Completed | Met primary |
| Phase 4 | NCT01229319 | Oct 2010 → Aug 2011 | actinic keratosis | Frankel, Amylynne, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT01203878 | Sep 2010 → Nov 2011 | actinic keratosis | Tennessee Clinical Research Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01161888 | Jun 2010 → Mar 2012 | lentigo maligna melanoma | Jerry Marsden | Completed | No outcome recorded |
| Phase 4 | NCT01059110 | Feb 2010 → Jan 2015 | plantar wart | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00849992 | Mar 2009 → Mar 2013 | actinic cheilitis | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 4 | NCT00777127 | Dec 2008 → Nov 2012 | actinic keratosis | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 4 | NCT00803907 | Dec 2008 → Sep 2012 | basal cell carcinoma | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT00774787 | Oct 2008 → Mar 2010 | actinic keratosis | Rigel Dermatology | Completed | No outcome recorded |
| Phase 4 | NCT00581425 | Dec 2007 → Sep 2011 | basal cell carcinoma | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT00116649 | Jun 2005 → May 2007 | actinic keratosis | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 4 | NCT00189293 | Jun 2005 → Dec 2007 | anogenital human papillomavirus infection | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 4 | NCT00115154 | May 2005 → Sep 2006 | actinic keratosis | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 4 | NCT00110682 | Apr 2005 → Oct 2006 | actinic keratosis, keratosis | Derm Research @ 888 Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00314756 | Mar → Nov 2005 | basal cell carcinoma | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT00761371 | Aug 2002 → Feb 2004 | skin disorder caused by infection | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 4 | NCT00204555 | Jan 2002 → Sep 2005 | skin basal cell carcinoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 4 | NCT00176943 | Oct 2000 → Aug 2002 | alopecia areata | Hordinsky, Maria K., MD | Completed | No outcome recorded |
| Phase 4 | NCT00177021 | Oct 2000 → Aug 2002 | alopecia areata | Hordinsky, Maria K., MD | Completed | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT06411106 | Jun 2024 → Sep 2025 | cutaneous lupus erythematosus | Centre for Human Drug Research, Netherlands | Unknown | No outcome recorded |
| — | NCT05315024 | Apr 2022 → Sep 2023 | influenza | The University of Hong Kong | Unknown | No outcome recorded |
| — | NCT02301494 | Apr 2020 → Apr 2022 | mycosis fungoides | Rochester General Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT03943407 | Nov 2019 → Jun 2021 | — | Aalborg University | Withdrawn | No outcome recorded |
| — | NCT04859361 | Nov 2018 → Apr 2020 | cervical intraepithelial neoplasia | University Medical Centre Maribor | Unknown | No outcome recorded |
| — | NCT03206138 | May 2017 → Oct 2018 | cervical intraepithelial neoplasia grade 2/3 | Seoul St. Mary's Hospital | Unknown | No outcome recorded |
| — | NCT02917746 | Nov 2016 → Jul 2018 | cervical intraepithelial neoplasia | Maastricht University Medical Center | Unknown | No outcome recorded |
| — | NCT01508884 | Jan → Dec 2012 | — | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT01935310 | Jul → Nov 2010 | hyperpigmentation of the skin | CES University | Completed | No outcome recorded |
| — | NCT00814528 | Nov 2007 → Sep 2009 | actinic keratosis | University of Chicago | Withdrawn | No outcome recorded |
| — | NCT00470392 | May 2007 → Jul 2010 | psoriasis | VA Office of Research and Development | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00504023 | Apr 2007 → Jan 2018 | vulva cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00585247 | Nov 2006 → Aug 2012 | capillary malformation | University of California, Irvine | Completed | No outcome recorded |
| — | NCT00463359 | — | basal cell carcinoma | University of Glasgow | Unknown | No outcome recorded |
| Comparator or background therapy42 trials | ||||||
| Phase 0 | NCT07077616 Background | Jul 2025 → Dec 2027 expected | glioma | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06305910 Background | Mar 2024 → Sep 2025 overdue | diffuse midline glioma, H3 K27M-mutant | OX2 Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT04072900 Background | Apr 2020 → Sep 2021 | cutaneous melanoma | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 1 | NCT03872947 Background | Apr 2019 → Jul 2026 | cholangiocarcinoma, colorectal cancer, fallopian tube cancer, gastric cancer +5 | Toray Industries, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02600949 Background | May 2016 → May 2027 expected | colorectal adenocarcinoma, pancreatic ductal adenocarcinoma | M.D. Anderson Cancer Center | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT02689726 Background | Aug 2015 → Aug 2016 | — | Genticel | Terminated | No outcome recorded |
| Phase 1 | NCT02276300 Background | Dec 2014 → Jul 2017 | breast cancer, gastric cancer | Technical University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT01803152 Background | Jan 2014 → Sep 2019 | bone sarcoma, soft tissue sarcoma | Macarena De La Fuente, MD | Completed | No outcome recorded |
| Phase 1 | NCT01808820 Background | Aug 2013 → Nov 2018 | anaplastic astrocytoma, glioblastoma | Macarena De La Fuente, MD | Completed | No outcome recorded |
| Phase 1 | NCT01795313 Background | Aug 2012 → Dec 2025 | ependymoma | James Felker | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01403285 Background | Aug 2011 → Apr 2014 | glioblastoma | Immatics Biotechnologies GmbH | Terminated | Met primary Stop: Enrollment |
| Phase 1 | NCT01264731 Comparator | Jan 2011 → Jun 2012 | melanoma | University of Virginia | Completed | No outcome recorded |
| Phase 1 | NCT01171469 Background | Sep 2010 → May 2012 | anaplastic astrocytoma, ependymoma, glioblastoma, medulloblastoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT00944580 Background | Jun 2009 → Aug 2010 | neuroblastoma, osteosarcoma, rhabdomyosarcoma | Penn State University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00638651 Comparator | Feb 2008 → Aug 2014 | — | University of Miami | Completed | No outcome recorded |
| Phase 1/2 | NCT02224599 Background | Jul 2017 → Aug 2018 | cancer | Kiromic BioPharma Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03559413 Background | Jun 2016 → Mar 2022 | childhood acute lymphoblastic leukemia | University Children's Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1/2 | NCT02078648 Background | May 2014 → Sep 2017 | adult glioblastoma | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05740969 Comparator | Feb 2023 → Feb 2024 | actinic keratosis | Ismail Gögenur | Unknown | No outcome recorded |
| Phase 2 | NCT05314127 Comparator | Apr → Oct 2022 | skin disorder caused by infection | Zagazig University | Unknown | No outcome recorded |
| Phase 2 | NCT02802943 Background | Oct 2016 → Sep 2022 | chronic lymphocytic leukemia/small lymphocytic lymphoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2 | NCT02482428 Comparator | May 2015 → May 2016 | anogenital human papillomavirus infection | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT02404389 Comparator | Mar 2015 → Jan 2016 | actinic keratosis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01957878 Background | Dec 2013 → Oct 2016 | human papilloma virus infection, viral sexually transmitted disease | Genticel | Completed | No outcome recorded |
| Phase 2 | NCT01543464 Background | May 2012 → Sep 2016 | melanoma | Inge Marie Svane | Terminated | No outcome recorded |
| Phase 2 | NCT01593124 Comparator | May 2012 → Apr 2013 | infective vaginitis | CONRAD | Completed | No outcome recorded |
| Phase 2 | NCT00335179 Comparator | Jan → Jul 2003 | actinic keratosis | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2/3 | NCT00941252 Comparator | Jul 2009 → Jan 2011 | cervical intraepithelial neoplasia | Medical University of Vienna | Completed | No outcome recorded |
| Phase 3 | NCT04143451 Comparator | Oct 2019 → Sep 2022 | influenza | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT03901690 Comparator | Aug 2019 → Mar 2020 | anogenital human papillomavirus infection | Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri | Unknown | No outcome recorded |
| Phase 3 | NCT03073967 Comparator | May 2017 → Aug 2025 | herpes simplex infectious disease | AiCuris Anti-infective Cures AG | Completed | Met primary |
| Phase 3 | NCT00894647 Comparator | May 2009 → Feb 2010 | actinic keratosis | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00605176 Comparator | Jan → Jul 2008 | actinic keratosis | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00603798 Comparator | Jan → Jul 2008 | actinic keratosis | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00129519 Comparator | Jan 2004 → Jan 2006 | basal cell carcinoma | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 4 | NCT01663558 Comparator | May → Dec 2015 | HIV infectious disease, anus disorder, human papilloma virus infection | United States Naval Medical Center, San Diego | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT02281682 Comparator | Nov 2014 → Jul 2018 | actinic keratosis | Maastricht University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01926496 Comparator | Sep 2013 → Jul 2019 | actinic keratosis | LEO Pharma | Completed | No outcome recorded |
| Phase 4 | NCT01538901 Comparator | Sep 2012 → Sep 2014 | actinic keratosis | Medical University of Vienna | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01413763 Comparator | Jul 2011 → Apr 2013 | actinic keratosis | Medicis Global Service Corporation | Unknown | No outcome recorded |
| — | NCT05146895 Comparator | Oct 2018 → Jun 2022 | human papilloma virus infection | First Hospital of China Medical University | Unknown | No outcome recorded |
| — | NCT00707174 Comparator | Mar 2005 → Mar 2013 | lentigo maligna melanoma | University of Utah | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-03-30 | Inovio Pharmaceuticals | Results INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia inovio.com ↗
Enrollment into the imiquimod arm was halted due to having no meaningful improvement upon the efficacy of VGX-3100 alone. |
| 2010-09-08 | Perrigo Company | Regulatory Perrigo Announces FDA Approval for Imiquimod Cream - Generic Equivalent to Aldara® perrigo.com ↗
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-03-30 | Inovio Pharmaceuticals | INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia inovio.com ↗ |
| 2010-09-08 | Perrigo Company | Perrigo Announces FDA Approval for Imiquimod Cream - Generic Equivalent to Aldara® perrigo.com ↗ |
| 2010-04-13 | Perrigo Company | Perrigo and Graceway Settle Litigation and Name Perrigo as the Authorized Generic Distributor for Aldara® perrigo.com ↗ |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 170 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | imiquimod | “An intradermal influenza vaccine preparations containing 15 μg of each of the three viral strains (Intanza®) will be administrated in the centre of the marked area after the...” NCT02960815 ↗159“TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)” NCT07077616 ↗ “Imiquimod cream is applied to the supraclavicular site followed by 2 supraclavicular injections of CD200AR-L each day for 2 consecutive days.” NCT06305910 ↗ “GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to the injection site 15 minutes and 24 hours after each vaccination.” NCT02689726 ↗ “ProCervix will be delivered with a topical agent, imiquimod, applied to the injection sites as a vaccine adjuvant.” NCT01957878 ↗ “Imiquimod cream is to be applied 5 of 7 days in a row with 2 days rest for a maximum of 2 cycles (total 6 weeks).” NCT03872947 ↗ “Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.” NCT00944580 ↗ “All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle.” NCT03943407 ↗ “Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week” NCT01543464 ↗ “Imiquimod 5% topical treatment, 3 times per week” NCT03073967 ↗ “250 mg imiquimod cream (12.5 mg imiquimod)” NCT00785122 ↗ |
| Known as | Aldara | “Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into...” NCT03472976 ↗19“In the imiquimod and intradermal vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2...” NCT02960815 ↗ “Aldara® (imiquimod) Cream, 5% was the first imiquimod product approved by the Food and Drug Administration (FDA) for the topical treatment of AK, superficial basal cell...” NCT02120898 ↗ “Imiquimod (Aldara; 3M Pharmaceuticals) is a novel immune response-activating compound, approved by the FDA for cervical warts, that activates macrophage killing of Leishmania species.” NCT01380314 ↗ “Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients” NCT00257530 ↗ “Double-Blind, Vehicle-Controlled Study to Evaluate Apoptosis in Basal Cell Carcinoma Treated With Aldara™ (Imiquimod) Cream, 5% Applied Once or Twice a Day” NCT00079300 ↗ “Imiquimod (Aldara, 3M) is one of the better characterized imidazoquinolines and is the only one currently approved for clinical use as a topical ointment.” NCT01792505 ↗ “All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.” NCT02802943 ↗ “GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to the injection site 15 minutes and 24 hours after each vaccination.” NCT02689726 ↗ “Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)” NCT00803907 ↗ “5 mg imiquimod (100mg Aldara®) per treatment site with a 12mm Finn chamber” NCT06411106 ↗ |
| Known as | Aldara (Imiquimod) | “Aldara (Imiquimod)” NCT00785122 ↗ |
| Known as | Aldara (imiquimod) 5% cream - 250 mg / packet | “Aldara (imiquimod) 5% cream - 250 mg / packet” NCT00189306 ↗ |
| Known as | Aldara (imiquimod) cream 5% | “Aldara® (imiquimod) cream 5%” NCT00116649 ↗ |
| Known as | Aldara 5% Topical Cream | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04859361 ↗ |
| Known as | Aldara cream | “Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.” NCT01400672 ↗ |
| Known as | IMI | “5% Imiquimod (IMI) cream” NCT02281682 ↗ |
| Known as | Imiquimod 5% cream | “Imiquimod 5% cream” NCT03233412 ↗ |
| Known as | Imiquimod Cream | “Drug: Imiquimod Cream” NCT03872947 ↗ |
| Known as | Imiquimod Cream (generic name) | “Imiquimod Cream (generic name)” NCT01686152 ↗ |
| Known as | IMQ | “In a previous phase II trial, we showed that topical imiquimod (IMQ) therapy is an efficacious treatment for high-grade squamous intraepithelial lesion (HSIL).” PMID 35177279 ↗ Feb 20223“This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I)” NCT01421017 ↗ “treatment with imiquimod (IMQ)” PMID 25885553 ↗ Apr 2015 “5% imiquimod (IMQ) 5%” PMID 31961446 ↗ Feb 2020 |
| Known as | TMX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01731652 ↗ |
| Known as | Zyclara | “Marketed by Medicis, Zyclara® (imiquimod) cream 2.5% is a safe and effective topical therapy for the treatment of AK of the face and scalp.” NCT02120898 ↗2“All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle.” NCT03943407 ↗ “Zyclara® (imiquimod Cream), 3.75% (Medicis)” NCT01686152 ↗ |
| Known as | Zyclara (imiquimod 3.75% cream) | “Zyclara (imiquimod 3.75% cream)” NCT01203878 ↗ |
| Known as | Zyclara, imiquimod | “Zyclara, imiquimod” NCT04859361 ↗ |
| Action | Activate | “topical imiquimod, a TLR7 agonist” PMID 18566444 ↗ Jul 2008 |
| Modality | Other / unclassified | “Aldara is a immune-response modifier.” NCT00177021 ↗ |
| Route | Topical | “Patients have topical imiquimod applied to the cervix” NCT00031759 ↗ |
| Target | TLR7 | “topical imiquimod, a TLR7 agonist” PMID 18566444 ↗ Jul 2008 |